

Pneumococcal Vaccine Timing–For Children

Age 2-23 Months

[View web version of this schedule.](#)

Standard

PCV15
Vaxneuvance® or
PCV20
Prevnar 20®

Age: 2 months

PCV15
Vaxneuvance® or
PCV20
Prevnar 20®

4 months

PCV15
Vaxneuvance® or
PCV20
Prevnar 20®

6 months

PCV15
Vaxneuvance® or
PCV20
Prevnar 20®

12–15 months

- Catch-up: Healthy children 24-59 months: 1-4 doses PCV15 or PCV20 depending on age and timing of past doses.

Age 2-18 Years With Underlying Condition(s)

- Children 2-18 years with any risk who have received all recommended doses before 6 years do not need further doses if they have received at least one dose of PCV20. If they have received PCV13 or PCV15, they should receive a dose of PCV20 OR PPSV23 (at least eight weeks after the prior dose of pneumococcal conjugate vaccine).
- Children 6-18 years with any risk who have not received any doses of PCV13, PCV15 or PCV20 should receive a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 >8 weeks later if not previously given.
- Children younger than 6 years of age should have received the standard or catch-up doses of PCV15 or PCV20. If PCV13 or PCV15 is used, follow with PPSV23 eight weeks later.
- Catch-up for Children 24-71 months with underlying conditions: 1-4 doses PCV15 or PCV20 depending on age and timing of past doses.

Risk Categories:

Chronic conditions:

- Chronic heart disease (particularly failure or cyanotic disease)
- Chronic kidney disease
- Chronic liver disease
- Chronic lung disease (including moderate persistent or severe persistent asthma)
- Diabetes mellitus
- CSF leaks or Cochlear implants

Immunocompromise:

- On maintenance dialysis or nephrotic syndrome
- Asplenia or splenic dysfunction
- Immunodeficiency (including B- to T- cell deficiency, complement deficiency and phagocytic disorders excluding CGD)
- Diseases and conditions treated with immunosuppressive drugs or radiation treatments (Including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease)
- HIV infection
- Sickle cell disease or other hemoglobinopathies
- Solid organ transplant

**PCV
20**
Prevnar 20®

OR

**PCV
15**
Vaxneuvance®

8 weeks

**PPSV¹
23**
Pneumovax® 23

1. When PPSV23 is used instead of PCV20 for children aged 2–18 years with an immunocompromising condition, either PCV20 or a second PPSV23 dose is recommended ≥5 years after the first PPSV23 dose.



For further details, see CDC's [Pneumococcal Vaccine Recommendations](#).

California Department of Public Health, Immunization Branch www.EZIZ.org

IMM-1159 (1/25)